Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 10/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31190971 | 1.00 | NAMPT (0.51) | NAMPTMAPKAPK2MAP4K4CYP17A1PSMB8 | |
| SCHEMBL1479164 | 0.86 | CDK8 (0.57) | MAPKAPK2MAP4K4 | |
| SCHEMBL27663662 | 0.83 | SMN1; SMN2 (0.52) | MAPKAPK2KIT | |
| SCHEMBL31378805 | 0.83 | KCNQ3 (0.53) | NAMPTMAPKAPK2CYP17A1 | |
| SCHEMBL6609814 | 0.83 | NAMPT (0.52) | NAMPTMAPKAPK2MAP4K4CYP17A1PSMB8 | |
| SCHEMBL535403 | 0.83 | KCNQ3 (0.53) | NAMPTMAPKAPK2CYP17A1 | |
| SCHEMBL30208803 | 0.83 | NAMPT (0.56) | NAMPTMAPKAPK2MAP4K4CYP17A1PSMB8 | |
| SCHEMBL376258 | 0.83 | NAMPT (0.56) | NAMPTMAPKAPK2MAP4K4CYP17A1PSMB8 | |
| SCHEMBL1548181 | 0.82 | MAPKAPK2 (0.47) | NAMPTMAPKAPK2MAP4K4CYP17A1PSMB8 | |
| SCHEMBL4910310 | 0.81 | NAMPT (0.51) | NAMPTMAPKAPK2MAP4K4CYP17A1PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117751117-A | SARM1 enzyme activity inhibitor and application thereof | 科辉智药生物科技（无锡）有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-115724839-A | SARM1 enzyme activity inhibitor and application thereof | 科辉智药生物科技(深圳)有限公司 | 2023-03-03 | — | — | CN | disclosed |
| WO-2021215280-A1 | NOVEL DIAMINE, POLYMER, LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| EP-2464228-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016194831-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2016-12-08 | — | — | WO | disclosed |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | disclosed |
| US-20140206662-A1 | Imidazopyridine Compounds | PROXIMAGEN LTD. (GB) | 2014-07-24 | — | — | US | disclosed |
| US-20140206662-A1 | Imidazopyridine Compounds | PROXIMAGEN LTD. (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | NAMPT 256/4885MAPKAPK2 431/4885MAP4K4 191/4885 |
| US-20120010188-A1 | Imidazopyridine Compounds | SSB, MIF, IDO1 | NAMPT 434/4885MAPKAPK2 2540/4885MAP4K4 1621/4885 |
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | NAMPT 1384/4885MAPKAPK2 2226/4885MAP4K4 1349/4885 |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | SSB, MIF, IDO1 | NAMPT 434/4885MAPKAPK2 2540/4885MAP4K4 1621/4885 |
| US-20140206662-A1 | Imidazopyridine Compounds | SSB, NFKBIA, TPMT | NAMPT 564/4885MAPKAPK2 1488/4885MAP4K4 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.